ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Abstract Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies. Similar phenotypes have been more recently also...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Molecular Cancer
المؤلفون الرئيسيون:	Yann Cheli, Meri K. Tulic, Najla El Hachem, Nicolas Nottet, Arnaud Jacquel, Maeva Gesson, Thomas Strub, Karine Bille, Alexandra Picard-Gauci, Henri Montaudié, Guillaume E. Beranger, Thierry Passeron, Pierre Close, Corine Bertolotto, Robert Ballotti
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2021-01-01
الموضوعات:	Melanoma ITGBL1 MITF
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12943-020-01306-2